Vimarsana
Biggest News Aggregation in the World

Mark Wildgust News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Wildgust. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Wildgust Today - Breaking & Trending Today

FDA Approves Easier-to-Swallow Imbruvica Formulation - Vimarsana News

FDA Approves Easier-to-Swallow Imbruvica Formulation

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

FDA Approves Label Expansion for Oral Ibrutinib Suspension in All Current Indications - Vimarsana News

FDA Approves Label Expansion for Oral Ibrutinib Suspension in All Current Indications

The FDA has approved a label expansion for ibrutinib with an oral suspension formulation in all current indications.

J&J Broadens Scope in Multiple Myeloma, Winning FDA Approval for New Drug - Vimarsana News

J&J Broadens Scope in Multiple Myeloma, Winning FDA Approval for New Drug

Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.

J&J sees trial data supporting earlier CAR-T use in multiple myeloma - Vimarsana News

J&J sees trial data supporting earlier CAR-T use in multiple myeloma

BioPharma

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma - Vimarsana News

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...